iX Biopharma enters China market with licensing agreement for erectile dysfunction drug

SINGAPORE (Apr 27): iX Biopharma has entered into a 10-year licensing agreement with Yiling Pharmaceutical in China for the licensing, supply, and distribution of Wafesil, a fast-dissolving sublingual sildenafil wafer for the treatment of male erectile dysfunction.

See also: iXBiopharma's Wafesil granted regulatory approval for treatment of male erectile dysfunction in Australia